Skip to content
researcher

Richard Morgan

Director of ICT

Faculty/Dept/School School of Pharmacy and Medical Sciences
(Faculty of Life Sciences)
Emailr.morgan3@bradford.ac.uk
Telephone +441274 233225

Biography

Qualifications
BA Hons. in Natural Sciences - Chemistry, Biochemistry, Mathematics and Statistics (2i). University of Cambridge 1990
Ph.D. in Biochemistry - University of Birmingham 1993
Previous positions
2006-2013 Senior Lecturer in Molecular Oncology, University of Surrey
2000-2006 Lecturer in Cell and Developmental Biology, St. George’s, University of London
1997-2000 Postdoctoral Scientist, Hubrecht Laboratory for Developmental Biology, Utrecht, The Netherlands
1993-1997 Postdoctoral Scientist, MRC National Institute for Medical Research, London
1990-1993 Postgraduate Student, University of Birmingham and ICI Pharmaceuticals, Cheshire  

Research

Oncology, Cancer biology, Biomarkers, Drug development, Transcription Oncology, Cancer biology, Biomarkers, Drug development, Transcription Oncology, Cancer biology, Biomarkers, Drug development, Transcription Current Projects My group is developing strategies to target the HOX / Engrailed family of homeodomain containing transcription factors in cancer. Work starting in 2004 gave rise to the currently only available antagonist of HOX function, HXR9, which represents a novel therapeutic approach in cancer. I have a number of active industrial collaborations to further develop this technology, including the synthesis of small molecule inhibitors of HOX proteins. In addition, we are studying the potential of HOX and Engrailed transcription factors as biomarkers for the diagnosis of a number of cancers including that of the prostate, lung and bladder. Our work has identified the EN2 transcription factor as a diagnostic marker for prostate cancer with twice the sensitivity of the currently used marker, PSA, and a high predictive value for tumour volume. EN2 is now undergoing clinical trials at multiple, international centres. Current Projects My group is developing strategies to target the HOX / Engrailed family of homeodomain containing transcription factors in cancer. Work starting in 2004 gave rise to the currently only available antagonist of HOX function, HXR9, which represents a novel therapeutic approach in cancer. I have a number of active industrial collaborations to further develop this technology, including the synthesis of small molecule inhibitors of HOX proteins. In addition, we are studying the potential of HOX and Engrailed transcription factors as biomarkers for the diagnosis of a number of cancers including that of the prostate, lung and bladder. Our work has identified the EN2 transcription factor as a diagnostic marker for prostate cancer with twice the sensitivity of the currently used marker, PSA, and a high predictive value for tumour volume. EN2 is now undergoing clinical trials at multiple, international centres. Current Projects My group is developing strategies to target the HOX / Engrailed family of homeodomain containing transcription factors in cancer. Work starting in 2004 gave rise to the currently only available antagonist of HOX function, HXR9, which represents a novel therapeutic approach in cancer. I have a number of active industrial collaborations to further develop this technology, including the synthesis of small molecule inhibitors of HOX proteins. In addition, we are studying the potential of HOX and Engrailed transcription factors as biomarkers for the diagnosis of a number of cancers including that of the prostate, lung and bladder. Our work has identified the EN2 transcription factor as a diagnostic marker for prostate cancer with twice the sensitivity of the currently used marker, PSA, and a high predictive value for tumour volume. EN2 is now undergoing clinical trials at multiple, international centres. Research Collaborations Dept Medicine, UCLA, USA St. George’s, University of London University of Kingston University of Essen Instituto Superiore Sanita, Rome Randox Diagnostics Ltd (UK) Zeus Diagnostics Inc (NJ, USA) Research Collaborations Dept Medicine, UCLA, USA St. George’s, University of London University of Kingston University of Essen Instituto Superiore Sanita, Rome Randox Diagnostics Ltd (UK) Zeus Diagnostics Inc (NJ, USA) Research Collaborations Dept Medicine, UCLA, USA St. George’s, University of London University of Kingston University of Essen Instituto Superiore Sanita, Rome Randox Diagnostics Ltd (UK) Zeus Diagnostics Inc (NJ, USA)
Date Role Title / Description Funder Award
- LeadTargeting HOX genes in cancer

Publications

Peer Reviewed Journal
TitleMembrane insertion and secretion of the Engrailed-2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stroma (2019)
AuthorsPunia, N.; Primon, Monika; Simpson, G.R.; Pandha, H.S.; Morgan, Richard
 
TitleKinase regulation of HOX transcription factors (2019)
AuthorsPrimon, Monika; Hunter, K.D.; Pandha, H.S.; Morgan, Richard
 
TitleKinase regulation of hox transcription factors (2019)
AuthorsPrimon M.;Hunter K.;Pandha H.;Morgan R.
JournalCancers
DOI10.3390/cancers11040508
 
TitleMembrane insertion and secretion of the Engrailed-2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stroma (2019)
AuthorsPunia N.;Primon M.;Simpson G.;Pandha H.;Morgan R.
JournalScientific Reports
DOI10.1038/s41598-019-41678-0
 
TitleEngrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer (2018)
AuthorsMcGrath, S.E.; Annels, N.; Madhuri, T.K.; Tailor, A.; Butler-Manuel, S.A.; Morgan, Richard; Pandha, H.; Michael, A.
 
TitleTargeting HOX-PBX interactions causes death in oral potentially malignant and squamous carcinoma cells but not normal oral keratinocytes (2018)
AuthorsPlatais, C.; Radhakrishnan, R.; Ebensberger, S.N.; Morgan, Richard; Lambert, D.W.; Hunter, K.D.
 
TitleEngrailed-2 (EN2) - A novel biomarker in epithelial ovarian cancer (2018)
AuthorsMcGrath S.;Annels N.;Madhuri T.;Tailor A.;Butler-Manuel S.;Morgan R.;Pandha H.;Michael A.
JournalBMC Cancer
DOI10.1186/s12885-018-4816-5
 
TitleTargeting HOX/PBX dimers in cancer (2017)
AuthorsMorgan, Richard; El-Tanani, Mohamed; Hunter, K.D.; Harrington, K.J.; Pandha, H.S.
 
TitleInhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells (2017)
AuthorsAlharbi, R.A.; Pandha, H.S.; Simpson, G.R.; Pettengell, R.; Poterlowicz, Krzysztof; Thompson, A.; Harrington, K.J.; El-Tanani, Mohamed; Morgan, Richard
 
TitleHOX transcription factors and the prostate tumor microenvironment (2017)
AuthorsMorgan, Richard; Pandha, H.S.
 
TitleMechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy (2016)
AuthorsEl-Tanani, Mohamed; Dakir, El-Habib; Raynor, Bethany; Morgan, Richard
 
TitleHOX transcription factors are potential targets and markers in malignant mesothelioma (2016)
AuthorsMorgan, Richard; Simpson, G.R.; Gray, S.; Gillett, C.; Tabi, Z.; Spicer, J.; Harrington, K.J.; Pandha, H.S.
 
TitleA seasonal switch in histone deacetylase gene expression in the hypothalamus and their capacity to modulate nuclear signaling pathways (2016)
AuthorsStoney, P.N.; Rodrigues, D.; Helfer, Gisela; Khatib, T.; Ashton, A.; Hay, E.A.; Starr, R.; Kociszewska, D.; Morgan, P.J.; McCaffery, P.J.
 
TitleHOX genes as potential markers of circulating tumour cells (2016)
AuthorsMorgan, Richard; El-Tanani, Mohamed
 
TitleRan GTPase promotes cancer progression via Met receptor-mediated downstream signaling (2016)
AuthorsYuen, H-F.; Chan, K.K.; Platt-Higgins, A.; Dakir, El-Habib; Matchett, K.B.; Haggag, Y.A.; Jithesh, P.V.; Habib, T.; Faheem, A.; Dean, F.A.; Morgan, Richard; Rudland, P.S.; El-Tanani, Mohamed
 
TitleThe prognostic significance of specific HOX gene expression patterns in ovarian cancer (2016)
AuthorsKelly, Z.; Moller-Levet, C.; McGrath, S.; Butler-Manuel, S.; Madhuri, T.K.; Kierzek, A.M.; Pandha, H.S.; Morgan, Richard; Michael, A.
 
TitleDisease map-based biomarker selection and pre-validation for bladder cancer diagnostic (2015)
AuthorsDe Paoli, M.; Perco, P.; Mühlberger, I.; Lukas, A.; Pandha, H.S.; Morgan, Richard; Feng, G.J.; Marquette, C.
 
TitleThe role of HOXB9 and miR-196a in head and neck squamous cell carcinoma (2015)
AuthorsDarda, L.; Hakami, F.; Morgan, Richard; Murdoch, C.; Lambert, D.W.; Hunter, K.D.
 
TitleTargeting HOX transcription factors in prostate cancer (2014)
AuthorsMorgan, Richard; Boxall, A.; Harrington, K.J.; Simpson, G.R.; Michael, A.; Pandha, H.S.
 
TitlePeptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma (2014)
AuthorsAndo, H.; Natsume, A.; Senga, T.; Watanabe, R.; Ito, I.; Ohno, M.; Iwami, K.; Ohka, F.; Motomura, K.; Kinjo, S.; Ito, M.; Saito, K.; Morgan, Richard; Wakabayashi, T.
 
TitleCorrelation of Urinary Engrailed-2 Levels to Tumour Volume and Pathological Stage in Men Undergoing Radical Prostatectomy (2013)
AuthorsPandha, H.S.; Javed, S.; Sooriakumaran, P.; Bott, S.; Montgomery, B.; Hutton, A.; Eden, C.; Langley, S.E.; Morgan, Richard